耐万古霉素感染：病例更新与临床特征综述
Vancomycin resistant infections: A review of case updating and clinical features.
作者信息
Cong Yanguang, Yang Sijin, Rao Xiancai
机构信息
Department of Clinical Laboratory, Traditional Medicine Hospital Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, China.
Department of Cardiovascular Disease, Traditional Medicine Hospital Affiliated to Southwest Medical University, Luzhou, Sichuan 646000, China.
出版信息
J Adv Res. 2019 Oct 12;21:169-176. doi: 10.1016/j.jare.2019.10.005. eCollection 2020 Jan.
The infection caused by methicillin-resistant (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, . isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant . (VRSA) is mediated by a gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.
耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染是对公共卫生的全球威胁。万古霉素仍然是治疗MRSA感染的一线药物之一。然而，近年来已出现对万古霉素完全耐药的分离株。耐万古霉素金黄色葡萄球菌（VRSA）由一个基因簇介导，该基因簇从耐万古霉素肠球菌转移而来。自2002年在美国密歇根州分离出第一株VRSA以来，全球已分离出52株VRSA菌株。在本文中，我们综述了VRSA的最新进展，重点介绍了其耐药机制、VRSA感染的特征以及临床治疗方法。
Zotero 插件